Lipocine (NASDAQ: LPCN) is a specialty pharmaceutical company that develops pharmaceutical products using its oral drug delivery technology in the areas of men’s and women’s health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Lipocine’s clinical development pipeline includes three development programs. TLANDO, designed to help restore normal testosterone levels in hypogonadal men, was well tolerated and met the primary efficacy end-points in phase 3 testing and is currently under FDA review. LPCN 1111 is being developed as a next-generation oral testosterone product and is currently in phase 2 testing. LPCN 1107 is a product candidate indicated for the prevention of recurrent preterm birth and is currently in phase 2 testing. LPCN 1107 has been granted Orphan Drug Designation by the FDA. For more information, visit the company’s website at www.lipocine.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
[email protected]
